Amvuttra

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. **Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process.** If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

Patient Height: _____*cm*

Please indicate the place of service for the requested drug:

❑ *Ambulatory Surgical (POS Code 24)*
❑ *Home (POS Code 12)*
❑ *Off Campus Outpatient Hospital (POS Code 19)*
❑ *On Campus Outpatient Hospital (POS Code 22)*
❑ *Office (POS Code 11)*

Drug Information:

Strength/Measure _____*Units* ❑ ml ❑ Gm ❑ mg ❑ ea ❑ Un

Directions(sig) _____*Route of administration* _____

Dosing frequency _____

What is the ICD-10 code? _____

Criteria Questions:

1. What is the diagnosis?

❒ Polyneuropathy of hereditary transthyretin-mediated amyloidosis (transthyretin-type familial amyloid polyneuropathy (ATTR-FAP)), *Continue to 2*

❒ Other, please specify. _____, *Continue to 2*

2. Was the diagnosis confirmed by detection of a mutation in the TTR gene? ***ACTION REQUIRED***: If Yes, attach a copy of testing or analysis confirming a mutation of the TTR gene.

Send completed form to: Priority Partners Fax: 1-866-212-4756

 JHHC PP Amvuttra SGM 5491-A – 10/2023.

Priority Partners ● 7231 Parkway Drive Suite 100 ● Hanover, MD 21076
Phone: 888-819-1043 ● Fax: 1-866-212-4756 ● www.hopkinshealthplans.org

❒ Yes ***ACTION REQUIRED****: Submit supporting documentation, Continue to 3*

❒ No*, Continue to 3*

❒ Unknown*, Continue to 3*

3. Does the patient exhibit clinical manifestations of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTR-FAP) (e.g., amyloid deposition in biopsy specimens, TTR protein variants in serum, progressive peripheral sensory-motor polyneuropathy)? ***ACTION REQUIRED***: If Yes, attach medical record documentation confirming the patient demonstrates signs and symptoms of polyneuropathy.
❒ Yes, *Continue to 4*
❒ No, *Continue to 4*

4. Is the patient a liver transplant recipient?
❒ Yes, *Continue to 5*
❒ No, *Continue to 5*

5. Will the requested medication be used in combination with either inotersen (Tegsedi), patisiran (Onpattro) or tafamidis (Vyndaqel, Vyndamax)?
❒ Yes, *Continue to 6*
❒ No, *Continue to 6*

6. Is the requested medication prescribed by or in consultation with any of the following: a) neurologist, b) geneticist, or c) physician specializing in the treatment of amyloidosis?
❒ Yes, *Continue to 7*
❒ No, *Continue to 7*

7. Is the request for a continuation of therapy with the requested drug?
❒ Yes, *Continue to 8*
❒ No, *No Further Questions*

8. Has the patient demonstrated a beneficial response to treatment with the requested drug therapy compared to baseline (e.g., improvement of neuropathy severity and rate of disease progression as demonstrated by the modified Neuropathy Impairment Scale+7 (mNIS+7) composite score, the Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) total score, polyneuropathy disability (PND) score, FAP disease stage, manual grip strength)? ***ACTION REQUIRED***: If Yes, attach chart notes or medical record documentation supporting a positive clinical benefit of the requested drug.
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by Priority Partners.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Priority Partners Fax: 1-866-212-4756